Diclofenac/Hyaluronic Acid

Abstract

▲ Topical gel containing 3% diclofenac in 2.5% hyaluronic acid (HYAL CT1101) is used for the treatment of actinic keratosis. ▲ In animal models, diclofenac in hyaluronic acid inhibited angiogenesis and induced neovascular regression in inflammatory tissue, and depleted substance P content in snout tissue. ▲ Diclofenac delivered in hyaluronic acid appears to accumulate in the epidermis of human skin in vitro and mice in vivo. ▲ Results of clinical trials indicate that topical HYAL CT1101 is effective in the treatment of actinic ker atosis. A clinical cure (all lesions fully resolved) was seen in 47% of 108 patients using HYAL CT1101 compared with 19% of patients using pla cebo after 3 months in 1 randomised, double-blind study. ▲ Mild to moderate skin irritation has been reported in up to 72% of patients treated with HYAL CT1101 in clinical studies.